Literature DB >> 2533905

Ondansetron: pre-clinical safety evaluation.

M L Tucker1, M R Jackson, M D Scales, N W Spurling, D J Tweats, K Capel-Edwards.   

Abstract

A programme of pre-clinical safety evaluation of ondansetron has been undertaken which involved a series of studies - single dose studies, repeat dose studies, reproduction studies, genotoxicity studies, oncogenicity studies, local irritancy studies, and a hypersensitivity study. Ondansetron was found to have a very good safety profile, and the only toxicity identified was associated with central nervous system activity when near lethal doses were administered. It was not genotoxic and had no reproductive or oncogenic potential.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2533905

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  3 in total

Review 1.  A risk-benefit assessment of pharmacological and nonpharmacological treatments for nausea and vomiting of pregnancy.

Authors:  P Mazzotta; L A Magee
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

2.  Placental transfer of ondansetron during early human pregnancy.

Authors:  Shing-Shun N Siu; Matthew T V Chan; Tze-Kin Lau
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Review of NVP and HG and Early Pharmacotherapeutic Intervention.

Authors:  Shannon M Clark; Maged M Costantine; Gary D V Hankins
Journal:  Obstet Gynecol Int       Date:  2011-11-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.